Biogen Idec, Inc. (BIIB) Misses Q2 EPS by 1c, Sales Beat; Guides FY11
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $209.15 -0.32%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $1.36, $0.01 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.18 billion.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Globant (GLOB) Misses Q2 EPS by 10c, Offers Guidance
- XP Inc. (XP) Tops Q2 EPS by 8c
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
